UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 571 - 585 of 671

<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>

Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg - Abstract
Tuesday, 21 August 2007
Urology Research Office, Royal Hallamshire Hospital, Sheffield, UK.
read more

Long-Term Efficacy of Tolterodine and Patient Compliance in Pediatric Patients with Neurogenic Detrusor Overactivity - Abstract
Tuesday, 21 August 2007
Department of Urology, Charité - Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
read more

Age Related Pathogenesis of Nocturia in Patients with Overactive Bladder - Abstract
Monday, 20 August 2007
Weill Cornell Medical Center, New York, New York 10021, USA. urojock@aol.com
read more

Long-Term Tolerability of Tolterodine Extended Release in Children 5-11 Years of Age: Results from a 12-Month, Open-Label Study - Abstract
Monday, 20 August 2007
University Medical Centre Groningen, Groningen, The Netherlands.
read more

The Clinical Efficacy of Tolterodine Extended-Release is Maintained for 24 h in Patients with Overactive Bladder - Abstract
Friday, 17 August 2007
Department of Urology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. roger.dmochowski@vanderbilt.edu
read more

The Effects of Tolterodine on Bladder-Filling Sensations and Perception Thresholds to Intravesical Electrical Stimulation: Method and Initial Results - Abstract
Friday, 17 August 2007
Neuro-Urology, Swiss Paraplegic Center, Balgrist University Hospital, Zurich, Switzerland.
read more

Verathon Technology Challenge Award Winners Announced at AUA: Winners from VA Boston/Harvard Honored
Friday, 01 June 2007
read more

AUA 2007 Plenary Session: Presidential Address; “The Survival of Urology: Was Darwin Right?”
Thursday, 24 May 2007
read more

Society of Urologic Nurses and Associates Releases Guide for Nurses New to Operating Room
Tuesday, 24 April 2007
read more

European Urology - Acetylcholine and the Overactive Bladder
Monday, 02 April 2007
Volume 51, Issue 4, Pages 881-883 (April 2007) Currently, the most widely used and effective pharmacologic treatment for the overactive bladder (OAB) is administration of muscarinic receptor antagonists.
read more

European Urology - Transdermal Oxybutynin: Sticking to the Facts
Monday, 02 April 2007
Volume 51, Issue 4, Pages 907-914 (April 2007) Abstract - Objectives: This article critically reviews all the available published and presented data about transdermal oxybutynin to provide a summary of its efficacy, tolerability, and acceptability.
read more

European Urology - Efficacy and Tolerability of Tolterodine Extended Release in Male and Female Patients with Overactive Bladder
Monday, 02 April 2007
Volume 51, Issue 4, Pages 1054-1064 (April 2007) Abstract - Objectives: To evaluate the efficacy and tolerability of tolterodine extended release (ER) in men and women with overactive bladder (OAB).
read more

SUFU 2007 - Dorsal Genital Nerve Stimulation for the Treatment of Refractory Overactive Bladder Symptoms
Thursday, 22 March 2007
read more

SUFU 2007 - Effects of Prior Therapy on Health-Related Quality of Life Following Treatment with Transdermal Oxybutynin
Thursday, 22 March 2007

read more

SUFU 2007 - A New Overactive Bladder Questionnaire & Severity Score
Wednesday, 21 March 2007
read more

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder